Evidence map›Paper›PMID 38385135›Full record

ArticleFrontiers in cardiovascular medicine2024

A pilot clinical assessment of biphasic asymmetric pulsed field ablation catheter for pulmonary vein isolation.

Bingwei Chen, Chang Lv, Yingjian Cui, Chengzhi Lu, Heng Cai, Zhixiao Xue, Xinyu Xu, Siying Su

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Bingwei Chen *School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Chang Lv *School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Yingjian Cui *School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Chengzhi LuDepartment of Cardiology, Tianjin First Central Hospital, Tianjin, China.
Heng CaiDepartment of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Zhixiao XueSchool of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Xinyu XuSchool of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Siying SuDepartment of Research and Development, Tianjin Intelligent Health Medical Co., Ltd., Tianjin, China.
Tianjin Medical University · CNTianjin First Center Hospital · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulsed field ablation (PFA) is a new treatment for atrial fibrillation (AF), and its selective ablation characteristics give it a significant advantage in treatment. In previous cellular and animal experiments, we have demonstrated that biphasic asymmetric pulses can be used to ablate myocardial tissue. However, small-scale clinical trials are needed to test whether this approach is safe and feasible before extensive clinical trials can be performed. Therefore, the purpose of this experiment is to determine the safety and feasibility of biphasic asymmetric pulses in patients with AF and is to lay the foundation for a larger clinical trial. Ablation was performed in 10 patients with AF using biphasic asymmetric pulses. Voltage mapping was performed before and after PFA operation to help us detect the change in the electrical voltage of the pulmonary veins (PV). 3-Dimensional mapping system showed continuous low potential in the ablation site, and pulmonary vein isolation (PVI) was achieved in all four PV of the patients. There were no recurrences, PV stenosis, or other serious adverse events during the 12 months follow-up. The results suggest that PFA using biphasic asymmetric waveforms for patients with AF is safe, durable, and effective and that a larger clinical trial could begin. Clinical Trial Registration: https://www.chictr.org.cn/, identifier, ChiCTR2100051894.

Indexed as

atrial fibrillationbiphasic asymmetric pulsepilot clinical assessmentpulmonary vein isolationpulsed field ablation

Identifiers

PMID38385135
PMCPMC10879394
OpenAlexW4391609593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.